Enhancement of the tumor penetration of monoclonal antibody by fusion of a neuropilin-targeting peptide improves the antitumor efficacy

Molecular Cancer Therapeutics

Volumn 13, Issue 3, 2014, Pages 651-661

  Shin, Tae Hwan ^a   Sung, Eun Sil ^a   Kim, Ye Jin ^a   Kim, Ki Su ^c   Kim, Se Ho ^c   Kim, Seok Ki ^d   Lee, Young Don ^b   Kim, Yong Sung ^a  

^a Ajou University   (South Korea)

^b Ajou University School of Medicine   (South Korea)

^c Mogam Biotechnology Research Institute   (South Korea)

^d National Cancer Center   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; IMMUNOGLOBULIN FC FRAGMENT; MONOCLONAL ANTIBODY; NEUROPILIN 1; NEUROPILIN 2; SEMAPHORIN 3A; TRASTUZUMAB; VASCULAR ENDOTHELIAL CADHERIN;

AMINO TERMINAL SEQUENCE; ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN BINDING; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLOOD VESSEL PERMEABILITY; CANCER THERAPY; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFICACY; DRUG PENETRATION; DRUG RECEPTOR BINDING; DRUG TARGETING; FEMALE; GENE FUSION; HUMAN; HUMAN CELL; MOLECULARLY TARGETED THERAPY; MOUSE; NEOPLASM; NONHUMAN; PERMEABILITY; PRIORITY JOURNAL; RECEPTOR AFFINITY; SOLID TUMOR; XENOGRAFT;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIGENS, CD; CADHERINS; CELL LINE, TUMOR; CELL-PENETRATING PEPTIDES; FEMALE; HUMANS; MICE; NEOPLASMS; NEUROPILINS; PROTEIN TRANSPORT; RECOMBINANT FUSION PROTEINS;

EID: 84896303254     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-13-0748     Document Type: Article

References (37)

1. Scott AM, Wolchok JD, Old LJ. Antibody therapy of cancer. Nat Rev Cancer 2012;12:278-87.
2. Marcucci F, Bellone M, Rumio C, Corti A. Approaches to improve tumor accumulation and interactions between monoclonal antibodies and immune cells. MAbs 2013;5:34-46.
3. Thurber GM, Schmidt MM, Wittrup KD. Antibody tumor penetration: transport opposed by systemic and antigen-mediated clearance. Adv Drug Deliv Rev 2008;60:1421-34.
4. Christiansen J, Rajasekaran AK. Biological impediments to monoclonal antibody-based cancer immunotherapy. Mol Cancer Ther 2004;3:1493-501. (Pubitemid 39562594)
5. Chauhan VP, Stylianopoulos T, Boucher Y, Jain RK. Delivery of molecular and nanoscale medicine to tumors: transport barriers and strategies. Annu Rev Chem Biomol Eng 2011;2:281-98.
6. Beckman RA, Weiner LM, Davis HM. Antibody constructs in cancer therapy: protein engineering strategies to improve exposure in solid tumors. Cancer 2007;109:170-9. (Pubitemid 46106231)
7. Sugahara KN, Teesalu T, Karmali PP, Kotamraju VR, Agemy L, Girard OM, et al. Tissue-penetrating delivery of compounds and nanoparticles into tumors. Cancer Cell 2009;16:510-20.
8. Sugahara KN, Teesalu T, Karmali PP, Kotamraju VR, Agemy L, Greenwald DR, et al. Coadministration of a tumor-penetrating peptide enhances the efficacy of cancer drugs. Science 2010;328:1031-5.
9. Teesalu T, Sugahara KN, Kotamraju VR, Ruoslahti E. C-end rule peptides mediate neuropilin-1-dependent cell, vascular, and tissue penetration. Proc Natl Acad Sci U S A 2009;106:16157-62.
10. Beyer I, van Rensburg R, Strauss R, Li Z, Wang H, Persson J, et al. Epithelial junction opener JO-1 improvesmonoclonal antibody therapy of cancer. Cancer Res 2011;71:7080-90.
11. Wild JR, Staton CA, Chapple K, Corfe BM. Neuropilins: expression and roles in the epithelium. Int J Exp Pathol 2012;93:81-103.
12. Acevedo LM, Barillas S, Weis SM, Gothert JR, Cheresh DA. Semaphorin 3A suppresses VEGF-mediated angiogenesis yet acts as a vascular permeability factor. Blood 2008;111:2674-80.
13. Le Guelte A, Galan-Moya EM, Dwyer J, Treps L, Kettler G, Hebda JK, et al. Semaphorin 3A elevates endothelial cell permeability through PP2A inactivation. J Cell Sci 2012;125:4137-46.
14. Roth L, Agemy L, Kotamraju VR, Braun G, Teesalu T, Sugahara KN, et al. Transtumoral targeting enabled by a novel neuropilin-binding peptide. Oncogene 2012;31:3754-63.
15. Grandclement C, Borg C. Neuropilins: a new target for cancer therapy. Cancers 2011;3:1899-928.
16. Vander Kooi CW, Jusino MA, Perman B, Neau DB, Bellamy HD, Leahy DJ. Structural basis for ligand and heparin binding to neuropilin B domains. Proc Natl Acad Sci U S A 2007;104:6152-7. (Pubitemid 47186064)
17. Appleton BA, Wu P, Maloney J, Yin J, Liang WC, Stawicki S, et al. Structural studies of neuropilin/antibody complexes provide insights into semaphorin and VEGF binding. EMBO J 2007;26:4902-12. (Pubitemid 350191304)
18. von Wronski MA, Raju N, Pillai R, Bogdan NJ, Marinelli ER, Nanjappan P, et al. Tuftsin binds neuropilin-1 through a sequence similar to that encoded by exon 8 of vascular endothelial growth factor. J Biol Chem 2006;281:5702-10. (Pubitemid 43847668)
19. Maione F, Capano S, Regano D, Zentilin L, Giacca M, Casanovas O, et al. Semaphorin 3A overcomes cancer hypoxia and metastatic dissemination induced by antiangiogenic treatment in mice. J Clin Invest 2012;122:1832- 48.
20. Maione F, Molla F, Meda C, Latini R, Zentilin L, Giacca M, et al. Semaphorin 3A is an endogenous angiogenesis inhibitor that blocks tumor growth and normalizes tumor vasculature in transgenic mouse models. J Clin Invest 2009;119:3356-72.
21. Sung ES, Park KJ, Choi HJ, Kim CH, Kim YS. The proteasome inhibitor MG132 potentiates TRAIL receptor agonist-induced apoptosis by stabilizing tBid and Bik in human head and neck squamous cell carcinoma cells. Exp Cell Res 2012;318:1564-76.
22. Song CH, Yang SH, Park E, Cho SH, Gong EY, Khadka DB, et al. Structure-based virtual screening and identifi cation of a novel androgen receptor antagonist. J Biol Chem 2012;287:30769-80.
23. Choi HJ, Kim YJ, Lee S, Kim YS. A heterodimeric Fc-based bispecific antibody simultaneously targeting VEGFR-2 and Met exhibits potent anti-tumor activity. Mol Cancer Ther 2013;12:2748-59.
24. Goldstein NI, Prewett M, Zuklys K, Rockwell P, Mendelsohn J. Biological efficacy of a chimeric antibody to the epidermal growth factor receptor in a human tumor xenograft model. Clin Cancer Res 1995;1:1311-8.
25. Baselga J, Norton L, Albanell J, Kim YM, Mendelsohn J. Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts. Cancer Res 1998;58:2825-31. (Pubitemid 28311914)
26. Lee CH, Park KJ, Sung ES, Kim A, Choi JD, Kim JS, et al. Engineering of a human kringle domain into agonistic and antagonistic binding proteins functioning in vitro and in vivo. Proc Natl Acad Sci U S A 2010;107:9567-71.
27. Kim A, Lee JY, Byun SJ, Kwon MH, Kim YS. Viral genome RNA degradation by sequence-selective, nucleic-acid hydrolyzing antibody inhibits the replication of influenza H9N2 virus without significant cytotoxicity to host cells. Antiviral Res 2012;94:157-67.
28. Gavard J, Gutkind JS. VEGF controls endothelial-cell permeability by promoting the beta-arrestin-dependent endocytosis of VE-cadherin. Nat Cell Biol 2006;8:1223- 34.
29. Lee CM, Tannock IF. The distribution of the therapeutic monoclonal antibodies cetuximab and trastuzumab within solid tumors. BMC Cancer 2010;10:255.
30. Rhoden JJ, Wittrup KD. Dose dependence of intratumoral perivascular distribution of monoclonal antibodies. J Pharm Sci 2012;101:860-7.
31. Adams RH, Lohrum M, Klostermann A, Betz H, Puschel AW. The chemorepulsive activity of secreted semaphorins is regulated by furin-dependent proteolytic processing. EMBO J 1997;16:6077-86. (Pubitemid 27458327)
32. Parker MW, Xu P, Li X, Vander Kooi CW. Structural basis for the selective vascular endothelial growth factor-A (VEGF-A) binding to neuropilin-1. J Biol Chem 2012;287:11082-9.
33. Salikhova A, Wang L, Lanahan AA, Liu M, Simons M, Leenders WP, et al. Vascular endothelial growth factor and semaphorin induce neuropilin-1 endocytosis via separate pathways. Circ Res 2008;103:e71-9.
34. Dejana E, Orsenigo F, Lampugnani MG. The role of adherens junctions and VE-cadherin in the control of vascular permeability. J Cell Sci 2008;121:2115-22.
35. Kang Y, Massague J. Epithelial-mesenchymal transitions: twist in development and metastasis. Cell 2004;118:277-9. (Pubitemid 39061108)
36. Nasarre P, Kusy S, Constantin B, Castellani V, Drabkin HA, Bagnard D, et al. Semaphorin SEMA3F has a repulsing activity on breast cancer cells and inhibits E-cadherin-mediated cell adhesion. Neoplasia 2005;7:180-9. (Pubitemid 40315995)
37. Becker PM, Waltenberger J, Yachechko R, Mirzapoiazova T, Sham JS, Lee CG, et al. Neuropilin-1 regulates vascular endothelial growth factor-mediated endothelial permeability. Circ Res 2005; 96:1257-65. (Pubitemid 40962103)